Cidara Therapeutics Inc. (CDTX) is heading in the right direction with an average volume of $235.90K


Witnessing the stock’s movement on the chart, on November 23, 2022, Cidara Therapeutics Inc. (NASDAQ: CDTX) had a quiet start as it plunged -5.45% to $0.66. During the day, the stock rose to $0.7323 and sunk to $0.66 before settling in for the price of $0.70 at the close. Taking a more long-term approach, CDTX posted a 52-week range of $0.40-$1.71.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Meanwhile, its Annual Earning per share during the time was 24.60%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 55.10%. This publicly-traded company’s shares outstanding now amounts to $70.22 million, simultaneously with a float of $63.36 million. The organization now has a market capitalization sitting at $47.93 million. At the time of writing, stock’s 50-day Moving Average stood at $0.6225, while the 200-day Moving Average is $0.6657.

If we measure the efficiency of the company that is accounted for 89 employees. For the Profitability, stocks gross margin was +99.62, operating margin was -85.24 and Pretax Margin of -85.67.

Cidara Therapeutics Inc. (CDTX) Ownership Facts and Figures

Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Cidara Therapeutics Inc.’s current insider ownership accounts for 1.20%, in contrast to 39.60% institutional ownership. According to the most recent insider trade that took place on Sep 19, this organization’s CFO & CBO sold 15,642 shares at the rate of 0.77, making the entire transaction reach 12,035 in total value, affecting insider ownership by 150,789. Preceding that transaction, on Sep 12, Company’s Chief Medical Officer sold 18,478 for 0.68, making the whole transaction’s value amount to 12,656. This particular insider is now the holder of 291,753 in total.

Cidara Therapeutics Inc. (CDTX) Earnings and Revenue Records

As on 6/29/2022, Multinational firm has announced its last quarter scores, in which it reported -$0.19 earnings per share (EPS) for the period topping the consensus outlook (set at -$0.28) by $0.09. This company achieved a net margin of -85.67 while generating a return on equity of -263.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.

Cidara Therapeutics Inc.’s EPS increase for this current 12-month fiscal period is 55.10% and is forecasted to reach -0.28 in the upcoming year.

Cidara Therapeutics Inc. (NASDAQ: CDTX) Trading Performance Indicators

Let’s observe the current performance indicators for Cidara Therapeutics Inc. (CDTX). It’s Quick Ratio in the last reported quarter now stands at 1.90. The Stock has managed to achieve an average true range (ATR) of 0.05. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.78.

In the same vein, CDTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.53, a figure that is expected to reach -0.15 in the next quarter, and analysts are predicting that it will be -0.28 at the market close of one year from today.

Technical Analysis of Cidara Therapeutics Inc. (CDTX)

Going through the that latest performance of [Cidara Therapeutics Inc., CDTX]. Its last 5-days volume of 0.3 million was inferior to the volume of 0.35 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 81.38% While, its Average True Range was 0.0521.


Please enter your comment!
Please enter your name here